Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Schoffski, P; Tan, DSW; Martin, M; Ochoa-de-Olza, M; Sarantopoulos, J; Carvajal, RD; Kyi, C; Esaki, T; Prawira, A; Akerley, W; De Braud, F; Hui, RN; Zhang, T; Soo, RA; Maur, M; Weickhardt, A; Krauss, J; Deschler-Baier, B; Lau, A; Samant, TS; Longmire, T; Chowdhury, NR; Sabatos-Peyton, CA; Patel, N; Ramesh, R; Hu, TC; Carion, A; Gusenleitner, D; Yerramilli-Rao, P; Askoxylakis, V; Kwak, EL; Hong, DS.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) +/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Journal for ImmunoTherapy of Cancer. 2022; 10(2): Nº de citas: 127 [doi:10.1136/jitc-2021-003776]

Muino, CB; Martin, M; del Monte-Millan, M; Garcia-Saenz, JA; Lopez-Tarruella, S.

HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Cancers. 2022; 14(3): Nº de citas: 2 [doi:10.3390/cancers14030512]

Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL; PALLAS groups and investigators.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(3): 282-293 Nº de citas: 167 [doi:10.1200/JCO.21.02554]

Lenz, HJ; Van Cutsem, E; Limon, ML; Wong, KYM; Hendlisz, A; Aglietta, M; Garcia-Alfonso, P; Neyns, B; Luppi, G; Cardin, DB; Dragovich, T; Shah, U; Abdullaev, S; Gricar, J; Ledeine, JM; Overman, MJ; Lonardi, S.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 161-170 Nº de citas: 478 [doi:10.1200/JCO.21.01015]

Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Lao, CD; Cowey, CL; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Butler, MO; Hill, A; Marquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schoffski, P; Carlino, MS; Lebbe, C; McArthur, G; Ascierto, PA; Daniels, GA; Long, GV; Bas, T; Ritchings, C; Larkin, J; Hodi, FS.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 127-137 Nº de citas: 798 [doi:10.1200/JCO.21.02229]

Alfano, F; Cordero-Grande, L; Ortuno, JE; Garcia, KF; Garcia-Sevilla, M; Zamora, OB; Conde, MH; Lizarraga, S; Santos, A; Pascau, J; Ledesma-Carbayo, MJ.

Breast Tumor Localization by Prone to Supine Landmark Driven Registration for Surgical Planning

IEEE Access. 2022; 10: 122901-122911 Nº de citas: 3 [doi:10.1109/ACCESS.2022.3223658]

Perez-Hernandez, C; Canovas, ML; Carmona-Bayonas, A; Escobar, Y; Margarit, C; Cervantes, JFM; Quintanar, T; Alfonso, AS; Virizuela, J.

A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study

Journal of Pain Research. 2022; 15: 2181-2196 Nº de citas: 3 [doi:10.2147/JPR.S365351]

Yau, C; Osdoit, M; van der Noordaa, M; Shad, S; Wei, J; de Croze, D; Harny, AS; Lae, M; Reyal, F; Sonke, GS; Steenbruggen, TG; van Seijen, M; Wesseling, J; Martin, M; del Monte-Millan, M; Lopez-Tarruella, S; Boughey, JC; Goetz, MP; Hoskin, T; Gould, R; Valero, V; Edge, SB; Abraham, JE; Bartlett, JMS; Caldas, C; Dunn, J; Earl, H; Hayward, L; Hiller, L; Provenzano, E; Sammut, SJ; Thomas, JS; Cameron, D; Graham, A; Hail, P; Mackintosh, L; Fan, F; Godwin, AK; Schwensen, K; Sharma, P; DeMichele, AM; Cole, K; Pusztai, L; Kim, MO; Veer, LJV; Esserman, LJ; Symmans, WF.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

LANCET ONCOLOGY. 2022; 23(1): 149-160 Nº de citas: 295 [doi:10.1016/S1470-2045(21)00589-1]

Calvo-Lopez, T; Paz-Cabezas, M; Llovet, P; Ibanez, MD; Sastre, J; Alonso-Orduna, V; Vieitez, JM; Yubero, A; Vera, R; Asensio-Martinez, E; Garcia-Alfonso, P; Aranda, E; Diaz-Rubio, E; Perez-Villamil, B.

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

Cancer Biomarkers. 2022; 34(2): 201-210 Nº de citas: 4 [doi:10.3233/CBM-210353]

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2022; 17(12): 1467-1473 Nº de citas: 10 [doi:10.1080/17425255.2021.2027908]

Munoz, AJ; de Toro, M; Ortega, L; Lopez, C; Gutierrez, A; Juliao, DS; Arregui, M; Lobato, N; Echavarria, I; Marquez-Rodas, I; Martin, M.

Venous thromboembolism incidence in cancer patients with germline BRCA mutations

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(1): 154-158 Nº de citas: 1 [doi:10.1007/s12094-021-02678-7]

Kalinsky, K; Barlow, WE; Gralow, JR; Meric-Bernstam, F; Albain, KS; Hayes, DF; Lin, NU; Perez, EA; Goldstein, LJ; Chia, SKL; Dhesy-Thind, S; Rastogi, P; Alba, E; Delaloge, S; Martin, M; Kelly, CM; Ruiz-Borrego, M; Gil-Gil, M; Arce-Salinas, CH; Brain, EGC; Lee, ES; Pierga, JY; Bermejo, B; Ramos-Vazquez, M; Jung, KH; Ferrero, JM; Schott, AF; Shak, S; Sharma, P; Lew, DL; Miao, J; Tripathy, D; Pusztai, L; Hortobagyi, GN.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. 2021; 385(25): 2336-2347 Nº de citas: 560 [doi:10.1056/NEJMoa2108873]

Bouza, E; Jimenez, MM; Alemany, L; Arribas, J; Banares, R; Barragan, MB; Bouza, JME; Felip, E; Fernandez-Capetillo, O; Gracia, D; Lopez-Velez, R; Mollar, JB; Munoz, P; Paz-Ares, L; Torne, A; Tovar, J; Valencia, E; Palomo, E.

Overview of virus and cancer relationships. Position paper

REVISTA ESPANOLA DE QUIMIOTERAPIA. 2021; 34(6): 525-555 Nº de citas: 6 [doi:10.37201/req/058.2021]

Sartore-Bianchi, A; Garcia-Alfonso, P; Geissler, M; Kohne, CH; Peeters, M; Price, T; Valladares-Ayerbes, M; Zhang, Y; Burdon, P; Taieb, J; Modest, DP.

Relationships Between Kohne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer

CLINICAL COLORECTAL CANCER. 2021; 20(4): 305-313 Nº de citas: 3 [doi:10.1016/j.clcc.2021.05.007]

Harbeck, N; Rastogi, P; Martin, M; Tolaney, SM; Shao, ZM; Fasching, PA; Huang, CS; Jaliffe, GG; Tryakin, A; Goetz, MP; Rugo, HS; Senkus, E; Testa, L; Andersson, M; Tamura, K; Del Mastro, L; Steger, GG; Kreipe, H; Hegg, R; Sohn, J; Guarneri, V; Cortes, J; Hamilton, E; Andre, V; Wei, R; Barriga, S; Sherwood, S; Forrester, T; Munoz, M; Shahir, A; San Antonio, B; Nabinger, SC; Toi, M; Johnston, SRD; O'Shaughnessy, J; monarchE Comm Members.

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

ANNALS OF ONCOLOGY. 2021; 32(12): 1571-1581 Nº de citas: 279 [doi:10.1016/j.annonc.2021.09.015]

Moura, DS; Pena-Chilet, M; Varela, JAC; Alvarez-Alegret, R; Agra-Pujol, C; Izquierdo, F; Ramos, R; Ortega-Medina, L; Martin-Davila, F; Castilla-Ramirez, C; Hernandez-Leon, CN; Romagosa, C; Salgado, MAV; Lavernia, J; Bague, S; Mayodormo-Aranda, E; Vicioso, L; Barcelo, JEH; Rubio-Casadevall, J; de Juan, A; Fiano-Valverde, MC; Hindi, N; Lopez-Alvarez, M; Lacerenza, S; Dopazo, J; Gutierrez, A; Alvarez, R; Valverde, C; Martinez-Trufero, J; Martin-Broto, J.

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

MOLECULAR ONCOLOGY. 2021; 15(12): 3691-3705 Nº de citas: 10 [doi:10.1002/1878-0261.12996]

Untch, M; Martin, M; de Laurentiis, M; Gligorov, J.

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

Oncology And Therapy. 2021; 9(2): 297-309 Nº de citas: 2 [doi:10.1007/s40487-021-00153-5]

Bastos-Oreiro, M; Ortiz, J; Pradillo, V; Salas, E; Marinez-Laperche, C; Munoz, A; Buno, I; Diez-Martin, JL; Soria, JM; Izquierdo, CP.

Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma

Cancer Medicine. 2021; 10(21): 7585-7592 Nº de citas: 8 [doi:10.1002/cam4.4280]